Compare Meta Platforms Inc (META) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Meta Platforms Inc vs ResMed Inc. — how do they compare? Meta Platforms Inc trades at $723.01 (market cap $1.84T), while ResMed Inc. trades at $225.92 (market cap $31.78B). The key difference: Meta Platforms Inc is far larger — about 57.9× ResMed Inc.'s market cap, and ResMed Inc. pays the higher dividend (1.17%). Which is the better fit depends on your goals — on Pluang, investors hold Meta Platforms Inc for 127 Days and ResMed Inc. for 51 Days on average.
| META | RMD | |
|---|---|---|
Market Cap | $1.84T | $31.78B |
Volume | 12,743,601 | 1,128,382 |
Sector | Media | Health |
52-Week High | $777.59 | $277.88 |
52-Week Low | $525.72 | $182.82 |
Typical Hold Time | 127 Days | 51 Days |
Enterprise Value | $1.86T | $31.14B |
Dividend Yield | 0.29% | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Meta Platforms (META) trades at $721.31, down 2.38% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish trend in moving averages but neutral oscillators, with key support at $719 and resistance at $726. Fundamentally, revenue grew to $200.97B in 2025 with a net income margin of 29.84%, though Q2 2026 EPS missed expectations. Recent news highlights the launch of the Muse Spark AI model and a legal ruling on a youth addiction lawsuit in Massachusetts.
The outlook for META remains positive with strong analyst support—80% recommend Buy and a consensus price target of $781.00—driven by AI innovation and revenue growth. However, risks include regulatory challenges and high capital expenditures. Investors should weigh robust profitability against legal and competitive pressures in the social media and AI sectors.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical outlook supported by moving averages and strong fundamentals. The company reported revenue of $5.15B in 2025, with net income of $1.40B and robust margins. Recent earnings beats and a dividend announcement highlight operational strength, while analyst consensus leans positive with a $242.70 price target.
Outlook remains favorable due to consistent EPS growth and market share gains, though risks include competitive pressures and ongoing legal investigations. The stock offers growth potential from healthcare demand tailwinds, but investors should monitor execution against guidance and macroeconomic factors affecting medical device spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
